David Sinclair (Life Biosciences) OSK human trials is now live. We will see OSK being injected into humans in 2026

#41

in my opinion, the new OSK research in recent 2 years have shown the risks u mentioned are mostly not present, though there remains more work to be done.

i def did not call it ‘the only real anti-aging technology’ in fact, i mentioned the reverse, that there are many other interesting research and applications.

OSK has been done in mice and primates and in primates it is safe and works as well. they are also doing it on human organoids and in vitro.

i dont take rapa, but it has been shown to can have serious side effects. if it works for you, great, i am happy.

i believe geroscience and medicine in general is undergoing not incremental breakthroughs but big breakthroughs currently. this is the opinion of david sinclair as well as many researchers and practitioners.

#42

What serious side effects? Tell us your opinion on rapamycin.

Main side effect is mouth sore. It also can worsen blood sugar and cholesterol for some. It can slightly increase chance of catching a cold or flu.

Was that it?

#43

Dunno i dont use it

U do? Feel free to share.

Its not avail over the counter here need a prescription and i have no interest in rapa personally.

#44

There is literally hundreds of responses to this question on another thread. Just do a search and you’ll find plenty of answers. No need to repeat IMO.

#45

This is also the rapamycin.news website and most people here take Rapamycin.

The side effects most people report are not serious.

I’ve had mouth sores a few times. That is all.

I generally feel good when I take Rapamycin.

3 Likes
#46

Is there anything you do currently take?

#47

Claims that we are close to doubling our average lifespans and just need to hang in there for a bit are so wrong they are dangerous and harmful for progress. There are far more limits that need to be overcome than just figure out how to use reprogramming therapies in vivo. Besides, even the reprogramming therapies are far away. We’re barely scratching the surface.

Yes he has had a large impact, much of it positive but not all impact is good. Awareness can be negative if it promotes hype and unreasonable expectations. So many older people that listen to him are going to think they have a chance of making it but they will be disappointed.

They didn’t live 100% longer. Their remaining lifespan was 100% longer. They started treatment in old age when the mice were 125 weeks old. Those given the therapy lived to about 145 weeks of age compared to control who lived to 135 weeks of age (so extra 20 weeks vs extra 10 weeks). That’s similar to treating 70 year olds humans with the therapy and seeing that they live to 80 while the controls live to 75. That’s an important benefit but nothing close to doubling lifespan or even getting close to the current maximum lifespan. Yes we would probably see larger benefits if treatment were started at younger ages, but I don’t think it would make a ton of difference. The benefits should be greaters at older ages since that’s when the cells are most in need of reprogramming.

4 Likes
#48

They injected mouse about to die basically and only had 10 or 20 weeks to activate it 1 off 1 on.

So the timing of osk was limited only 1 or 2 months of osk treatment.

And its likely that they couldnt rejuvenate all cells full body in the experiment due to limited proliferation of osk

#49

Yes but a lot of cells that didn’t get OSK activation from the gene therapy wouldn’t have gotten it even if you treated the mice with the therapy from a young age.

The OSK factors are transcription factors not cells. They do not replicate. What limits the delivery such that not all cells are reprogrammed is the viral vector delivery method. Those methods are not good enough to reach all the cells in the body.

Also there is another problem here. Different cells will require different amounts of reprogramming factors for reprogramming. Too much or too little could cause problems. There is no delivery method that can deliver different doses to different cells depending on what each cell needs. We don’t even have a way to measure the state of each individual cell in the body to determine the dose each one needs in the first place. That’s a ridiculously difficult problem to solve and we are nowhere close.

3 Likes
#50

This is an order of magnitude more dangerous than Rapamycin IMO.

I do have a PhD in cell biology, run a lab, and we have two papers published using temporary reprogramming (OKSM) for regeneration, and have been invited to write a commentary on other reprogramming papers. So I’d call myself reasonably credible in this field.

With that said, I am quite surprised it’s going forwards in humans, in any capacity. Even without the c-Myc, I see this as a fairly risky approach which is not well established and there’s a huge amount we don’t know. For example, as @Olafurpall has alluded to, this is very sensitive to the dose, timing etc. Reprogram too much and cells lose their function, de-differentiate, and even become pluripotent and form tumours. That will be extremely detrimental. If you reprogram optic nerve cells too much, they will stop being nerve cells at all, and there’s no coming back from that.

However, I do believe in the scientific principle that a temporary, controlled, partial reprogramming can rejuvenate cells, because I’ve seen it with my own eyes in my lab and others.

Delivery is crazy difficult, and we can’t control which cells receive the reprogramming factors, or how much. You just kinda inject it around the area and cross your fingers. Most of the work is done in mouse models, and often we us genetically edited mice which can enable OSK(m) using drugs like doxycycline or tamoxifen - but those techniques are not applicable to humans. For humans, I assume they’re using AAV. We can try to develop some sort of specificity using promoter driven expression, but it’s still not well defined. It’s also extremely dependent on the type of cell, so what works well for an optic nerve neurone may not work for a muscle cell or a liver cell.

So yes, I think it’s very cool that people are pushing this forwards. But it has to be done very carefully. Racing ahead, taking too many risks etc could backfire spectacularly. If someone develops a nasty teratoma behind their eye the whole stem cell and reprogramming field will be tarnished for at least a decade. The last thing we need is some sort of celebrity hype man over-selling this.

11 Likes
#51

Well said. I’ve read a lot of studies on reprogramming I agree with all you said about the difficulty and risks of such therapies at the current stage we’re at.

#52

but david sinclair has done this OSK thing in mouse models and primates and no teratomas was detected

regarding the delivery issue, yes that is well known, he pointed it out himself it is a delivery issue to solve at this stage as OSK (without M) works. i assume it works well enough within organs but delivering full body is a big issue.

it rewinds the cell’s age to a certain point but does not go to pluripotency but still keeps it differentiated and young.

i wonder what your thoughts are on the above, given you are an expert at this and most of us on this forum are not.

#53

We know enhanced autophagy has merits and SOX2 encourages enhanced autophagy. My issue with reprogramming is that it assumes that there is somewhere a backup copy of the program without identifying where it is. I do myself think there is a program and that the pointer in the program for any particular cell type is the level of nuclear acetylation in a non stressed cell (without hyperacetylation). However, that does not mean that dedifferentiating cells is a good idea.

I agree entirely with what you say.

1 Like
#54

From the Shiftbioscience website:

SB000 expression does not induce pluripotency with absence of iPSC colonies (white dotted lines).

image
image1138×870 425 KB

#55

Hey, thanks for the question. I’m not familiar with the exact details of what Sinclair is doing to give really specific comments yet. Do you have links to the key studies? I’d be happy to read them.

#56

Hey relaxed

Here are the seminal papers

Reprogramming to recover youthful epigenetic information and restore vision

Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma

https://journals.sagepub.com/doi/10.1089/cell.2023.0074

Reprogramming Factors Activate a Non-Canonical Oxidative Resilience Pathway That Can Rejuvenate RPEs and Restore Vision

Lifebiosciences links:

https://clinicaltrials.gov/study/NCT07290244

#57

Interesting.

A few points though:

  1. They seem to be competitors with lifebiosciences

2.The pictures seem to be in vitro and they are not in their publications only on their website as far as i can tell, i may be wrong.

3.I think sinclairs lab would have done the same in vitro experiments plenty of times before going to in vivo in mouse and primates models and patenting osk.

They would have detected ipscs and teratomas easily.

So not sure how much weight to put on those pics.

But its gd news for us all that we are seeing multiple genes being identified.

#58

Epigenetic Reprogramming & AI-Driven Longevity

Report Date: April 17, 2026
Subject: Analysis of Dr. David Sinclair’s “Information Theory of Aging” and AI-Accelerated Drug Discovery.
Source: Sinclair & Bilyeu: AI Just Compressed 160 Years of Aging Research

I. Executive Summary

This analysis distills the current paradigm shift in longevity science from descriptive observation to predictive manipulation, facilitated by high-throughput AI screening and epigenetic reprogramming. The core thesis—the Information Theory of Aging—posits that aging is not a result of irreversible hardware (DNA) damage but rather the degradation of software (epigenetic) integrity. Sinclair argues that cells maintain a “backup copy” of youthful information, accessible via the induction of specific transcription factors (OSK: Oct4, Sox2, Klf4).

Technologically, the integration of Agentic AI systems (e.g., K-Dense) has compressed roughly 160 years of traditional bench science into months. These systems have screened upwards of 8 billion virtual molecules to identify small-molecule mimetics of OSK gene therapy, aiming to democratize age reversal.

Clinical momentum is high. Life Biosciences received FDA IND clearance in January 2026 for ER-100, an epigenetic reprogramming therapy targeting glaucoma, with human trials beginning this month Lifespan.io, 2026. However, significant translational gaps remain. While optic nerve regeneration and “de-aging” of organoids (micro-brains, uteri) have been demonstrated in mice and non-human primates, systemic human age reversal remains speculative. The primary safety risk is the potential for dedifferentiation (pluripotency), which could trigger teratomas or oncogenesis if the “observer” mechanism (the cellular brake on reprogramming) fails.

II. Insight Bullets

  1. Information Theory Thesis: Aging is a loss of digital-to-analog information (epigenetic noise), not necessarily physical DNA decay.
  2. The “Backup Copy”: Cells contain a latent youthful state; identifying the “observer” (the mechanism storing this state) is the current lab priority.
  3. AI Compression: Large-scale virtual screening screened 8 billion molecules; traditional methods would require 160 years and billions in USD.
  4. OSK Paradigm: The Yamanaka factors (Oct4, Sox2, Klf4) can reset cellular age by ~75% without reaching 0% (pluripotency).
  5. Doxycycline Induction: The current OSK gene therapy uses doxycycline as a “switch” to activate the reprogramming genes.
  6. Nerve Regeneration: Primate studies demonstrated 100% regrowth of the optic nerve after laser-induced damage, challenging the dogma that CNS nerves cannot regrow.
  7. Organoid Research: Sinclair’s lab has successfully “de-aged” human micro-brains and is currently growing 3D human uteri to treat infertility.
  8. NAD+ & Fertility: Mouse data shows NAD+ repletion restores egg quality in weeks; human observational data suggests similar potential for IVF outcomes.
  9. Biological Clocks: Multi-agent AI (K-Dense) has invented “uncertainty-aware” transcriptomic clocks with higher accuracy than previous Markov models Agarwal et al., 2025.
  10. Metabolic Substrates: Ketones (e.g., Beta-hydroxybutyrate) act as signaling molecules that modify histone tails (acetylation/butyrylation), impacting gene expression beyond fuel.
  11. DNA Breakage (ICE Mouse): Inducing precise, non-mutagenic DNA breaks distracts sirtuins, accelerating aging phenotypes without mutations—proving the epigenetic noise theory.
  12. Nattokinase Efficacy: Clinical data indicates 10,800 FU/day can significantly reduce carotid intima-media thickness (CIMT) Frontiers, 2022.
  13. LP(a) Management: High LP(a) levels (Ashkenazi heritage) are being managed with high-dose statins and experimental PCSK9 inhibitors.
  14. Pluripotency Risk: Over-expression of Yamanaka factors (specifically c-Myc) carries a high risk of cancer; Sinclair’s OSK (minus Myc) mitigates but does not eliminate this.
  15. Democratization: The objective is to move from $100k+ gene therapies to a mass-marketed “reprogramming pill” (Paradigm 88).

III. Adversarial Claims & Evidence Table

Claim from Video Speaker’s Evidence Scientific Reality (Current Data) Evidence Grade Verdict
OSK Reverses Aging in Humans Primate data; imminent human trials. ER-100 FDA IND cleared for glaucoma (Jan 2026). Human data pending. Lifespan, 2026 B/D Plausible (Translational)
NAD+ IV Rescues Human Egg Quality N=1 pilot study mentioned; mouse data. Mouse data strong (Cell Reports 2020). Human RCTs for IV NAD+ in fertility are sparse/ongoing. Bertoldo, 2020 D Speculative (Clinical)
Nattokinase Dissolves Plaque Anecdotal / Lab observations. Large clinical study (N=1,062) showed reduction in carotid plaque at 10,800 FU/day. Chen et al., 2022 B Strong Support
Aging is Information Loss (ICE Model) “ICE” mouse publication (2023). Cell (2023) publication confirms epigenetic relocalization causes aging in mice. Human validation lacks direct “reversal” proof. Yang et al., 2023 C/D Strong Support (Mechanism)
Resveratrol is Effective for Longevity Personal stack; Sirtuin activation. Meta-analyses show mixed results in humans; bioavailability remains the primary bottleneck. Smith et al., 2022 A Unsupported (Lifespan)

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Grade A/B Evidence)

  • Atherosclerosis Management: Supplementation with Nattokinase (10,800 FU/day) for CIMT reduction, provided no contraindications with blood thinners.
  • Glycemic Control: Aggressive management of HbA1c (Target: <5.2%) via Berberine (500-1500mg/day) or Metformin (requires MD) to prevent glycation-induced protein damage.
  • Lipid Partitioning: Screening for LP(a); management with statins or PCSK9 inhibitors if levels exceed 30 mg/dL.
  • Lifestyle Fundamentals: 10-minute high-intensity sessions (3x/week), total sugar avoidance, and 15+ hour intermittent fasting to trigger endogenous ketosis.

Experimental Tier (Grade C/D Evidence)

  • NAD+ Optimization: NMN (1g/day) or NR to maintain Sirtuin activity. Note: Potential risk of accelerating existing occult malignancies (theoretical).
  • Polyphenol Loading: High-purity Resveratrol (1g/day) mixed with fat (yogurt/olive oil) for absorption.
  • Senolytic Support: Use of Quercetin/Fisetin (Fisetin at 20mg/kg for 2 days/month) based on Mayo Clinic protocols, though human longevity data is pending.

Red Flag Zone (Safety Data Absent)

  • Self-Administered OSK: Unauthorized “biohacker” use of OSK/Yamanaka factors via viral vectors or research chemicals. Extremely High Risk for teratoma formation.
  • Chronic Doxycycline Use: Using doxycycline as a perpetual gene inducer disrupts the microbiome and promotes antibiotic resistance.

V. Technical Mechanism Breakdown

  1. Epigenetic Noise & RCM Hypothesis: In response to double-strand breaks (DSBs), chromatin modifiers (e.g., SIRT1) relocalize to the site of damage. Over time, these proteins fail to return to their original loci, leading to the desilencing of genes (e.g., a skin cell expressing liver enzymes). This “cellular identity crisis” is the definition of aging in the ICE model.
  2. mTOR vs. Sirtuins: While not the focus of this video, the interaction involves mTOR inhibition (via fasting/rapamycin) and Sirtuin activation (via NAD+/Resveratrol). These pathways are counter-regulatory; Sirtuins act as “guardians” of the genome, while mTOR acts as a “builder” of the proteome.
  3. DNA Methylation Clocks: AI-driven clocks (K-Dense) measure the specific cytosine methylation patterns (CpG sites) that correlate with chronological age. The “reprogamming” process physically removes these methyl groups to reset the clock.
  4. Partial Reprogramming (OSK): Unlike full reprogramming to iPSCs (induced pluripotent stem cells), partial reprogramming halts the process before the cell loses its somatic identity. The “observer” or backup copy is hypothesized to be a subset of stable epigenetic marks that allow the cell to navigate back to its 25-year-old state rather than its 0-year-old (embryonic) state.
#59

World-first: therapy to make cells young again trialled in a person
A participant in a landmark clinical trial has been given a cellular-reprogramming treatment that aims to rejuvenate damaged cells in the eye.

https://www.nature.com/articles/d41586-026-01836-7

2 Likes
#60

They are trying to replicate their success in restoring eyesight of mice.

https://eye.hms.harvard.edu/news/scientists-reverse-age-related-vision-loss-eye-damage-glaucoma-mice

January 05, 2021

A team of researchers at Harvard Medical School (HMS) and Mass Eye and Ear have successfully restored vision in elderly mice by turning back the clock on their aged nerve cells in the retina to recapture their youthful function. The team used an adeno-associated virus as a vehicle to deliver into the retinas of mice three youth-restoring genes—Oct4, Sox2 and Klf4—that are normally switched on during embryonic development.

Zhigang He, PhD, Professor of Neurology and Ophthalmology at HMS, worked with HMS scientists David Sinclair, PhD, and Yuancheng Lu, PhD, to test whether the regenerative capacity of young animals could be imparted to adult mice, delivering a modified three-gene combination via an AAV into retinal ganglion cells of adult mice with optic nerve injury. The treatment resulted in a two-fold increase in the number of surviving retinal ganglion cells after the injury and a five-fold increase in nerve regrowth.

A longevity startup has dosed its first patient with a drug to reverse age-related sight loss.

Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.

It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain. ER-100 is designed to rejuvenate those cells so that they work again and restore sight.

6 Likes